GSK India Q1 FY27 Results: PAT Up 24% YoY to ₹253 Crore; Revenue Up 15%

What Happened ?

GSK India announced its Q1 FY27 financial results, reporting revenue of ₹924 crore, up 15% YoY, and PAT of ₹253 crore, up 24% YoY. The company delivered strong growth across both its core and innovative portfolios, reflecting continued progress in its portfolio transformation strategy, supplemented by execution excellence, and a favourable base effect from the comparable period last year.

key details

• Revenue up 15% YoY to ₹924 crore.
• PAT up 24% YoY to ₹253 crore.
• EBITDA margin at 32%.
• General Medicines portfolio: Top 5 promoted brands outperforming market; Augmentin, Ceftum, T-Bact leadership positions reinforced.
• Respiratory portfolio: Nucala (mepolizumab) benefitting large number of patients; Trelegy Ellipta gaining traction.
• Vaccines business: Leadership in self-pay private paediatric vaccines; Infanrix Hexa and Fluarix Tetra driving growth; Shingrix gaining adoption in adult vaccination.
• Oncology business: Jemperli now leading immunotherapy for first-line primary advanced and recurrent endometrial cancer; Zejula among top PARP inhibitors in maintenance treatment of recurrent ovarian cancer.
• Supply chain resilience strengthened through diversified sourcing and enhanced contingency planning.
• Pipeline launches: Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy (RSV vaccine for adults 60+ and high-risk adults 50-59).

Note:

• The Oncology business, led by Jemperli and Zejula, has grown significantly since its launch in August 2025. Together, both therapies have touched the lives of a growing number of women suffering from gynecological malignancies, with GSK committed to expanding access and patient reach.

Risk Analysis

Summary:

• While the company delivered strong Q1 performance with broad-based growth, risks include regulatory changes, competition, and supply chain dynamics.

Key Risks:

• Regulatory changes in pharmaceutical pricing and patent regulations.
• Intense competition in General Medicines, Vaccines, and Oncology segments.
• Supply chain disruptions and raw material availability.
• Clinical trial outcomes and product approvals.
• Currency fluctuations affecting import costs.
• Pipeline launch execution and market adoption risks.

Worst Case:

• Regulatory price controls or delays in pipeline launches could impact revenue growth and margin trajectory.

Risk Level: Low to Medium

Company Commentary

Management highlighted that:

• Mr. Bhushan Akshkar, Managing Director, GSK India: “GSK India’s broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business.”
• “This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development.”
• “With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India.”